Table 3.
Risk of Primary and Secondary Outcomes at 2-year follow-up*
| Endpoints | All patients (n = 120) | DCB-only group (n = 58) | Hybrid group (n = 62) | Odds ratio (95% CI) | P value |
|---|---|---|---|---|---|
| Patients with clinical follow-up | 114 (95.00%) | 56 (96.55%) | 58 (93.55%) | - | - |
| TLR | 6 (5.26%) | 2 (3.57%) | 4 (6.90%) | 0.500 (0.088-2.845) | 0.679 |
| MACE† | 9 (7.89%) | 4 (7.14%) | 5 (8.62%) | 0.815 (0.207-3.207) | 1.000 |
| Cardiac death | 2 (1.75%) | 2 (3.57%) | 0 (0.00%) | - | 0.439 |
| TVMI | 2 (1.75%) | 0 (0.00%) | 2 (3.45%) | - | 0.496 |
| Periprocedural | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | - | - |
| Non-periprocedural | 2 (1.75%) | 0 (0.00%) | 2 (3.45%) | - | 0.496 |
| Vessel thrombosis | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | - | 1.000 |
| Definite | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | - | - |
| Probable | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | - | - |
*
CI denotes confidence interval, DCB drug-coated balloon, DES drug-eluting stent, MACE major adverse cardiovascular events, TLR target lesion revascularization, and TVMI target vessel myocardial infarction.
†
MACE defined as the composite outcome of cardiac death, TLR, TVMI, and vessel thrombosis.